Arif KALKANLI, Cem Tuğrul GEZMİŞ, Arif ÖZKAN, Fatih YANARAL, Zafer TANDOĞDU, Memduh AYDIN, Nusret Can ÇİLESİZ

Comparison of Single and Prolonged Fluoroquinolone Prophylaxis and Risk Factors for Infectious Complications After Transrectal Prostate Biopsy

Background: The ideal prophylaxis duration for transrectalultrasonography-guided prostate biopsy is incompletely defined.Aims: To compare the infectious complications of transrectalultrasonography-guided prostate biopsy with and without extendedantibiotic prophylaxis. The secondary aim was to evaluate the riskfactors for infectious complications.Study Design: Prospective observational study.Methods: Four hundred patients who underwent transrectalultrasonography-guided prostate biopsy were recruited. Patientsorally received either 750 mg ciprofloxacin 60 min before theprocedure or 500 mg ciprofloxacin twice a day for a duration of 7days with the initial dose administered 24 h prior to the procedure.All patients were followed-up for 4 weeks after the transrectalultrasonography-guided prostate biopsy procedure for infectiouscomplications. Screening of urine was carried out in all patients onthe 3rd and 7th day after the procedure. Medical histories of all patientswere collected prior to biopsy. Information on medical history includethe following: hospitalization, urethral catheterization, or urinary tractinfections within the past 12 months; antibiotic use within the last3 months, prior urinary tract interventions, and previous transrectalultrasonography-guided prostate biopsy and Charlson comorbidityindexes. Ultrasound-guided biopsy was carried out using GeneralElectric’s 7 MHz transrectal ultrasound device in the left decubitusposition. Patients received one of the two ciprofloxacin-basedprophylaxis regimens. Subsequent transrectal ultrasonographyguidedprostate biopsy to all patients were followed-up for 30 days.Further follow-up of patients was carried out on the second and fourthweeks after transrectal ultrasonography-guided prostate biopsy, andsymptoms, such as dysuria, rectal bleeding, fever, hematospermia,hematuria, and pollakiuria, were recorded.Results: Both groups presented similar baseline characteristics andmedical history. Infectious complication rates within the 4-weekfollow-up were similar in both groups (single dose: 3% vs prolonged:3%) (p>0.05). In both groups, infectious complications significantlyincreased than that at previous antibiotic usage (single: p=0.028;prolonged: p=0.040). Non-infectious complication ratios showed nosignificant variation (p>0.05).Conclusion: Pre-operative single dose of 750 mg oral ciprofloxacincompared with 7 days prolonged treatment resulted in similarinfectious complication outcomes in patients undergoing transrectalultrasonography-guided prostate biopsy. The use of antibioticswithin the last 3 months increases the risk for post-transrectalultrasonography-guided prostate biopsy infectious complications.

PDF

___

Taylor S, Margolick J, Abughosh Z, Goldenberg SL, Lange D, Bowie WR, et al. Ciprofloxacin resistance in the faecal carriage of patients undergoing transrectal ultrasound guided prostate biopsy. BJU Int 2013;111:946-53.
Zani EL, Clark OAC, Rodrigues Netto N Jr. Antibiotic prophylaxis for transrectal prostate biopsy. Cochrane Database Syst Rev 2011:CD006576.
Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R,et al. Systematic review of complications of prostate biopsy. Eur Urol 2013;64:876-92.
Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61:1079-92.
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013;39:165-228.
Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2017;71:618-29.
Grabe M, Bartoletti R, Johansen TEB,Cai T, Çek M,Köves B, et al. Guidelines on Urological Infections: European Association of Urology, 2017
Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309-32.
Urinary Tract Infection (Catheter-Associated Urinary Tract Infection [CAUTI] and Non-Catheter-Associated Urinary Tract Infection [UTI]) and Other Urinary System Infection [USI]) Events: Center of Disease control and prevention, 2016.
Tandogdu Z, Bartoletti R, Cai T, Çek M, Grabe M, Kulchavenya E, et al. Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003-2013. World J Urol 2016;34:1193-200.
Tukenmez Tigen E, Tandogdu Z, Ergonul O, Altinkanat G, Gunaydin B, Ozgen M, et al. Outcomes of Fecal Carriage of Extended-spectrum β-Lactamase After Transrectal Ultrasound-guided Biopsy of the Prostate. J Urol 2014;84:1008-15.
Liss MA, Taylor SA, Batura D, Steensels D, Chayakulkeeree M, Soenens C, et al. Fluoroquinolone resistant rectal colonization predicts risk of infectious complications after transrectal prostate biopsy. J Urol 2014;192:1673-8.
Steensels D, Slabbaert K, De Wever L, Vermeersch P, Van Poppel H, Verhaegen J. Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy: should we reassess our practices for antibiotic prophylaxis? Clin Microbiol Infect 2012;18:575-81.
Liss MA, Chang I, Santos R, Nakama-Peeples A, Peterson EM, Osann K, et al. Prevalence and Significance of Fluoroquinolone Resistant Escherichia coli in Patients Undergoing Transrectal Ultrasound Guided Prostate Needle Biopsy. J Urol 2011;185:1283-8.
Briffaux R, Merlet B, Normand G, Coloby P, Leremboure H, Bruyère F, et al. Short or long schemes of antibiotic prophylaxis for prostate biopsy. A multicentre prospective randomized study. Prog Urol 2009;19:39-46.
Cam K, Kayikci A, Akman Y, Erol A. Prospective assessment of the efficacy of single dose versus traditional 3-day antimicrobial prophylaxis in 12-core transrectal prostate biopsy. Int J Urol 2008;15:997-1001.
Taylor AK, Zembower TR, Nadler RB, Scheetz MH, Cashy JP, Bowen D, et al. Targeted Antimicrobial Prophylaxis Using Rectal Swab Cultures in Men Undergoing Transrectal Ultrasound Guided Prostate Biopsy is Associated With Reduced Incidence of Postoperative Infectious Complications and Cost of Care. J Urol 2012;187:1275-9
Van de Sande-Bruinsma N, Grundmann H, Verloo D, Tiemersma E, Monen J, Goossens H, et al. Antimicrobial drug use and resistance in Europe. Emerg Infect Dis 2008;14:1722-30.
Shandera KC, Thibault GP, Deshon GE Jr. Variability in patient preparation for prostate biopsy among American urologists. Urology 1998;52:644-6.
Hillelsohn JH, Duty B, Blute ML Jr, Okhunov Z, Kashan M, Moldwin R, et al. Variability of transrectal ultrasound-guided prostate biopsy prophylactic measures. Can J Urol 2012;19:6573-7.
Çek M, Tandoğdu Z, Naber K, Tenke P, Wagenlehner F, van Oostrum E, et al. Antibiotic prophylaxis in urology departments, 2005-2010. E Urol 2013;63:386-94.
Kapoor DA, Klimberg IW, Malek GH, Wegenke JD, Cox CE, Patterson AL. Singledose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology 1998;52:552-8.
Bratzler DW, Houck PM; Surgical Infection Prevention Guideline Writers Workgroup. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Am J Surg 2005;189:395-404.
Aron M, Rajeev TP, Gupta NP. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int 2000;85:682-5.
4. Bruyère F, Malavaud S, Bertrand P, Decock A, Cariou G, Doublet JD, et al. Prosbiotate: a multicenter, prospective analysis of infectious complications after prostate biopsy. J Urol 2015;193:145-50.
Wagenlehner FM, van Oostrum E, Tenke P, Tandogdu Z, Çek M, Grabe M, et al. Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study Eur Urol 2013;63:521-7.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Cli. 2005;55:74-108.
National Cancer Institute. National Institutes of Health 2016.